| # | Title | Journal | Year | Citations |
|---|
| 1 | HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis | Pediatric Blood and Cancer | 2007 | 4,018 |
| 2 | Transfusion related acute lung injury: A pediatric perspective | Pediatric Blood and Cancer | 2005 | 595 |
| 3 | Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work‐up, and treatment for patients till the age of 18 years | Pediatric Blood and Cancer | 2013 | 496 |
| 4 | Sirolimus for the treatment of complicated vascular anomalies in children | Pediatric Blood and Cancer | 2011 | 470 |
| 5 | Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis | Pediatric Blood and Cancer | 2008 | 469 |
| 6 | The pediatric preclinical testing program: Description of models and early testing results | Pediatric Blood and Cancer | 2007 | 430 |
| 7 | Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) soft‐tissue Sarcoma committee experience and rationale for current COG studies | Pediatric Blood and Cancer | 2012 | 326 |
| 8 | Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors | Pediatric Blood and Cancer | 2011 | 318 |
| 9 | The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report from the childhood cancer survivor study | Pediatric Blood and Cancer | 2014 | 311 |
| 10 | Liver transplantation for hepatoblastoma: Results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience | Pediatric Blood and Cancer | 2004 | 308 |
| 11 | Proton versus photon radiotherapy for common pediatric brain tumors: Comparison of models of dose characteristics and their relationship to cognitive function | Pediatric Blood and Cancer | 2008 | 306 |
| 12 | Standards for the Psychosocial Care of Children With Cancer and Their Families: An Introduction to the Special Issue | Pediatric Blood and Cancer | 2015 | 297 |
| 13 | Children's Oncology Group's 2013 blueprint for research: Neuroblastoma | Pediatric Blood and Cancer | 2013 | 285 |
| 14 | Uncommon histiocytic disorders: The non-Langerhans cell histiocytoses | Pediatric Blood and Cancer | 2005 | 279 |
| 15 | A worldwide collaboration to harmonize guidelines for the long‐term follow‐up of childhood and young adult cancer survivors: A report from the international late effects of Childhood Cancer Guideline Harmonization Group | Pediatric Blood and Cancer | 2013 | 275 |
| 16 | Risk factors for diabetes insipidus in langerhans cell histiocytosis | Pediatric Blood and Cancer | 2006 | 271 |
| 17 | Soft tissue sarcoma across the age spectrum: A population‐based study from the surveillance epidemiology and end results database | Pediatric Blood and Cancer | 2011 | 270 |
| 18 | Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000–2004 | Pediatric Blood and Cancer | 2008 | 248 |
| 19 | The epidemiology of hepatoblastoma | Pediatric Blood and Cancer | 2012 | 246 |
| 20 | Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab | Pediatric Blood and Cancer | 2013 | 246 |
| 21 | Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial | Pediatric Blood and Cancer | 2006 | 238 |
| 22 | Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials | Pediatric Blood and Cancer | 2007 | 234 |
| 23 | Risk of recurrence and survival after relapse in patients with Ewing sarcoma | Pediatric Blood and Cancer | 2011 | 228 |
| 24 | Standards of Psychosocial Care for Parents of Children With Cancer | Pediatric Blood and Cancer | 2015 | 227 |
| 25 | A proposal for an international retinoblastoma staging system | Pediatric Blood and Cancer | 2006 | 225 |
| 26 | Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society?Late Effects Study Group | Pediatric Blood and Cancer | 2004 | 224 |
| 27 | Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO) | Pediatric Blood and Cancer | 2019 | 220 |
| 28 | PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report | Pediatric Blood and Cancer | 2013 | 219 |
| 29 | Sickle cell disease related mortality in the United States (1999-2009) | Pediatric Blood and Cancer | 2013 | 215 |
| 30 | The British Childhood Cancer Survivor Study: Objectives, methods, population structure, response rates and initial descriptive information | Pediatric Blood and Cancer | 2008 | 210 |
| 31 | Long‐term outcome of 4,040 children diagnosed with pediatric low‐grade gliomas: An analysis of the Surveillance Epidemiology and End Results (SEER) database | Pediatric Blood and Cancer | 2014 | 210 |
| 32 | Age is an independent prognostic factor in rhabdomyosarcoma: A report from the soft tissue sarcoma committee of the children's oncology group | Pediatric Blood and Cancer | 2004 | 207 |
| 33 | Outcome of children less than three years old at diagnosis with non‐metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols | Pediatric Blood and Cancer | 2008 | 206 |
| 34 | Prospective medical assessment of adults surviving childhood cancer: Study design, cohort characteristics, and feasibility of the St. Jude Lifetime Cohort Study | Pediatric Blood and Cancer | 2011 | 206 |
| 35 | A meta-analysis of the neurocognitive sequelae of treatment for childhood acute lymphocytic leukemia | Pediatric Blood and Cancer | 2007 | 204 |
| 36 | Epidemiologic analysis of 1,442 children and adolescents registered in the German germ cell tumor protocols | Pediatric Blood and Cancer | 2004 | 198 |
| 37 | Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: Implications for screening and prevention | Pediatric Blood and Cancer | 2005 | 196 |
| 38 | Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP) | Pediatric Blood and Cancer | 2010 | 195 |
| 39 | Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical features | Pediatric Blood and Cancer | 2013 | 193 |
| 40 | Effects of physical therapy intervention for children with acute lymphoblastic leukemia | Pediatric Blood and Cancer | 2004 | 192 |
| 41 | The problem of treatment abandonment in children from developing countries with cancer | Pediatric Blood and Cancer | 2007 | 190 |
| 42 | A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study | Pediatric Blood and Cancer | 2008 | 186 |
| 43 | Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma | Pediatric Blood and Cancer | 2007 | 185 |
| 44 | A quantitative meta‐analysis of neurocognitive sequelae in survivors of pediatric brain tumors | Pediatric Blood and Cancer | 2010 | 184 |
| 45 | Comparison of FDG‐PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis | Pediatric Blood and Cancer | 2009 | 180 |
| 46 | Incidence of Langerhans cell histiocytosis in children: A population‐based study | Pediatric Blood and Cancer | 2008 | 179 |
| 47 | MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma | Pediatric Blood and Cancer | 2007 | 176 |
| 48 | A Fitbit and Facebook mHealth intervention for promoting physical activity among adolescent and young adult childhood cancer survivors: A pilot study | Pediatric Blood and Cancer | 2017 | 172 |
| 49 | Factors associated with health-related quality of life in pediatric cancer survivors | Pediatric Blood and Cancer | 2007 | 171 |
| 50 | Symptoms in the palliative phase of children with cancer | Pediatric Blood and Cancer | 2007 | 171 |
